Sonoma Pharmaceuticals to Present at Trickle Research and LD Micro Investor Conferences
BOULDER, CO / ACCESSWIRE / March 28, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing...
Pharmaceutical
Rett Syndrome Research Trust selects PMD Solutions’ RespiraSense In Their Upcoming US-Based Biosensor Validation Study – VIBRANT
STOCKHOLM, SE / ACCESSWIRE / March 28, 2024 / PMD Device Solutions (FRA:8T0)(STO:PMDS) Rett Syndrome Research Trust (RSRT) is proud...
Akanda Corp. Announces Canmart’s Plans for Facebook and Instagram Social Shopping Technology Integration
London, United Kingdom--(Newsfile Corp. - March 28, 2024) - Akanda Corp. ("Akanda" or the "Company") (NASDAQ: AKAN), an international medical...
Mobix Labs Broadens Product Portfolio to Include Medical Technology Sector
--End Users include GE HealthCare and PerkinElmerIRVINE, Calif.--(BUSINESS WIRE)--Mobix Labs, Inc. (Nasdaq: MOBX) (“Mobix Labs” or the “Company”), a fabless...
Akanda Corp. Announces Strategic Plan to Evaluate and Enter Bitcoin, Blockchain, AI Segments of the Cannabis Market
London, United Kingdom--(Newsfile Corp. - March 28, 2024) - Akanda Corp. (NASDAQ: AKAN) ("Akanda" or the "Company"), an international medical...
Laxxon Medical to Participate in 23rd Annual Needham Virtual Health Conference
NEW YORK, NY / ACCESSWIRE / March 28, 2024 / Laxxon Medical, a leading pharma-technology company pioneering a new generation...
Third Harmonic Bio Appoints Geoff McDonough, M.D., to its Board of Directors
SAN FRANCISCO, March 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing...
Dyadic Announces Change in Board and Management Leadership Roles
JUPITER, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI),...
Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results
First Patient Enrolled in Phase 3 LEVEL Trial Evaluating TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension from Heart...
Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis
As the first-ever U.S. Food and Drug Administration (FDA) approved over-the-counter (OTC) naloxone in 2023, Emergent is working to expand access...
Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference
HANOVER, MD, March 28, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical...
Molecular Templates Announces $9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase Agreement
AUSTIN, Texas, March 28, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company...
Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights
On track for topline data from CAN-2409 phase 3 in localized intermediate/high risk prostate cancer, expected in Q4 2024Results from...
Tevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion Price
WARREN, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings ('Tevogen Bio') (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech...
Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day
CORAL GABLES, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company...
Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors
David Norton Assumes Role of Interim Board Chair while the Company Runs a Global Search for a New ChairLONDON, March...
CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting
- New 12-month data from the Phase 3 BOND-003 trial to be featured in an oral presentation in the Paradigm-shifting,...
Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual Meeting
CUPERTINO, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage...
Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference
WESTLAKE VILLAGE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing...
Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update
Conference Call and Webcast Today at 4:30 p.m. ET2023 Highlights and Anticipated 2024 Milestones XACIATO™ (clindamycin phosphate) vaginal gel 2%...